The Drug Company is a member of the Grenoble Technology Cluster known as Minalogic and scientific focus and interest is based upon the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface. The technology has the potential capability of delivering controlled dosages of drugs needed and prescribed for an individual.
About 15 years ago, MIT professors Robert Langer and Michael Cima had the idea to develop a programmable, wirelessly controlled microchip that would deliver drugs after implantation in a patient's body. This week, the MIT researchers and scientists from MicroCHIPS Inc. reported that they have successfully used such a chip to administer daily doses of an osteoporosis drug normally given by injection.
The human clinical trial began in Denmark in January 2011.
Does anyone know when mPhase began their human clinical trials? Thanks in advance.
Very bright for the owners of mphase as long as they can get suckers to buy stock the lenders dump on news that only idiots could take as positive. Yes very bright indeed as long as there are dim bulbs like you.